An Appeals Court Has Upheld Bayer’s $182M Judgement Against Takeda in the Hemophilia Drug Fight

(Reuters) – A federal appeals court has upheld a $182 million judgment in favor of Bayer in a patent infringement lawsuit targeting Takeda Pharmaceutical Co unit Baxalta Inc’s hemophilia drug Adynovate.

A unanimous Federal Circuit U.S. Court of Appeals panel on Monday rejected Baxalta’s argument that the patent was not infringed and was invalid for lack of enablement, though it also rebuffed Bayer’s cross-appeal seeking a new trial on the issue of willfulness.

“We are very pleased by the Federal Circuit’s affirmance of Bayer’s jury trial win against Baxalta, which involved a number of legally intricate issues including claim construction, infringement, enablement, damages, and supplemental damages,” Sidley Austin partner Jim Badke, lead counsel for Bayer, said in a statement.